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Abbreviations: 
T1D - type 1 diabetes, CD – coeliac disease, TGA – anti-tissue 
transglutaminase autoantibodies, ATPA – anti-H+/K+-ATPase 
autoantibodies, TPOA – anti-thyroid peroxidase autoantibodies, RIA – 
radioimmunoassay, MA – multiple autoimmunity, IAA – anti-insulin 
autoantibodies, GADA – anti-glutamate decarboxylase autoantibodies, IA-
2A – anti-islet antigen-2 autoantibodies, ZnT8A – anti-zinc transporter-8 
autoantibodies, PCR-SSP – polymerase chain reaction with sequence 
specific primers. 
 
Summary  
Individuals with type 1 diabetes (T1D) are at increased risk of coeliac disease 
(CD), autoimmune thyroiditis and autoimmune gastritis, but the absolute 
risks are unclear. The aim of this study was to investigate the prevalence of 
autoantibodies to tissue transglutaminase (TGA), thyroid peroxidase 
(TPOA), and gastric H+/K+-ATPase (ATPA) and their genetic associations 
in a well-characterised population-based cohort of individuals with T1D 
from the Bart’s-Oxford family study for whom islet autoantibody prevalence 
data were already available. Autoantibodies in sera from 1072 patients 
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(males/females 604/468; median age 11.8 years, median T1D duration 2.7 
months) were measured by radioimmunoassays; HLA class II risk genotype 
was analysed in 973 (91%) using PCR-SSP. The prevalence of TGA (and/or 
history of CD), TPOA and ATPA in patients was 9.0%, 9.6%, and 8.2%, 
respectively; 3.2% had two or more autoantibodies. Females were at higher 
risk of multiple autoimmunity; TGA/CD were associated with younger age, 
and TPOA with older age. ATPA were uncommon in patients under 5 years, 
and more common in older patients. Anti-glutamate decarboxylase 
autoantibodies were highly predictive of co-existing TPOA/ATPA. 
TGA/CD were associated with HLA DR3-DQ2, with the DR3-DQ2/DR3-
DQ2 genotype conferring the highest risk, followed by DR4-DQ8/DR4-
DQ8. ATPA were associated with DR3-DQ2, DRB1*0404 (in males) and 
the DR3-DQ2/DR4-DQ8 genotype (in females). TPOA were associated with 
the DR3-DQ2/DR3-DQ2 genotype. Almost one quarter of patients 
diagnosed with T1D under 21 years have at least one other organ specific 
autoantibody. HLA class II genetic profiling may be useful in identifying 
those at risk of multiple autoimmunity.  
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Introduction 
Type 1 diabetes (T1D) is one of the major chronic disorders of childhood 
with a steady increase in incidence over the last few decades 1-5. 
Approximately half of the susceptibility to T1D is derived from genetic 
factors, the rest depends on environmental triggers 1, 6-9. Autoimmune 
diseases associated with T1D are often subclinical, and complications are 
usually recognized retrospectively. Along with the deleterious impact on 
general health, they can negatively affect glycaemic status in patients with 
T1D. For example, impaired thyroid function (hypothyroidism) in 
autoimmune thyroiditis or malabsorption resulting from coeliac disease 
(CD) lead to frequent hypoglycaemic episodes and poor glycaemic control 
10, 11. The long latent stage of autoimmune diseases, when only 
autoantibodies are present without clinical signs, highlights the opportunity 
for prevention strategies 12.  
Analysis of the literature showed large variations in reported frequencies of 
CD in children with T1D, ranging from 3.3% to 12%  13-15, while in the 
general population the prevalence is estimated at 1-2% 16. Autoimmune 
gastritis is present in 5-10% of T1D patients, while in the general population 
the average prevalence is 2% 17. Autoimmune thyroiditis is one of the most 
frequent autoimmune diseases associated with T1D. The prevalence of 
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thyroid antibodies varies considerably in different studies; it was estimated 
to be 5-40% in children 18-22  and 18-30% in adults with T1D 19, 20, 23 
compared with 3-5% and 8-24% in healthy controls, respectively 23, 24. 
Thyroid hypofunction, which is a sign of progressive thyrocyte damage, was 
present in 6-10% of patients with T1D, and the prevalence increased after 
the age of 50 years, eventually reaching 18% in the over 60s 25.  
Numerous studies in the last few decades have suggested common pathways 
and genetic elements involved in the development of autoimmune disorders, 
but few included patients with multiple autoimmunity (MA). Recent genome 
wide association studies have underlined the contribution of HLA to the 
development of different autoantibodies in T1D 26, but the genetic 
determinants critical to the development of MA are not well defined. This 
study aimed to identify the interplay between genetic determinants and co-
existent non-islet autoimmunity in patients with T1D.    
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Materials and Methods 
Patients 
A cohort of children and young adults (n=1072, 468 females, median age 
11.8 years, range 0.8-28 years; median age at T1D onset 10.9 years, range 
0.4-21 years; median T1D duration 2.7 months, range 0-16.4 years) with 
T1D from the well-characterized population-based Bart’s-Oxford (BOX) 
family study was investigated. Since 1985, the study has been recruiting 
individuals under the age of 21 years with newly-diagnosed T1D and their 
first-degree relatives (residents of the area formerly administered by Oxford 
Regional Health Authority, UK), of whom 76% are still in regular contact 
with the study 4. For the majority (86%) of the cohort, serum samples were 
available close to diagnosis (within 2 years), while sera from the rest were 
collected post-diagnosis (within 2-16 years). Thirty-seven (3.4%) patients 
were diagnosed with CD, as reported by questionnaire. Genetic samples 
(whole blood or mouth brush) were available from 973 participants (91%) 
27, of whom 958 (98%) were tested for all three non-islet autoantibodies. 
The BOX study is currently approved by the South Central - Oxford C 
National Research Ethics Committee. Participants provided informed, 
written consent and the study was performed according to the principles of 
the Declaration of Helsinki. 
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Methods 
Autoantibody measurement by radioimmunoassay 
Autoantibodies specific for the T1D specific antigens, insulin (IAA), 
glutamate decarboxylase (GADA), islet antigen-2 (IA-2A) and zinc 
transporter 8 (ZnT8A), as well as the CD specific antigen tissue 
transglutaminase (TGA IgG/IgA), were measured using fully-validated in-
house radioimmunoassays (RIAs) as described  previously 28, 29. Of the 1072 
patients, 1071 (99%) were tested for TGA. 
The measurement of autoimmune gastritis specific anti-H+/K+-ATPase 
autoantibodies (ATPA IgG) was performed in 1055 of the 1072 patients 
(98%) using a newly established in-house RIA. Plasmid pcDNA3.1 with the 
ATP4A gene encoding a 251 amino acid fragment of the H+/K+-ATPase 4A 
polypetide 30, 31 was used for in vitro transcription and translation in the TnT 
coupled reticulocyte system (Promega, Madison, WI, USA) to obtain 35S 
methionine labelled human-H+/K+-ATPase. Radioactive antigen (20000 cpm 
at 25 µl) bound by serum antibodies (incubated for 19-21 hours) was 
precipitated with protein-A sepharose (GE Healthcare, Sweden) and 
measured in a beta scintillation counter. Standards were prepared from a 
serum highly positive for ATPA, serially diluted with seronegative human 
serum, spanning the range from 0.4 (1/1024) to 100 arbitrary units/ml (1/4). 
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The inter-assay coefficients of variation for positive control samples were 
14% at 24 units/ml and 23% at 79 units/ml. Thyroid autoimmunity was 
assessed in 1066 of the 1072 patients (99%) by measurement of anti-thyroid 
peroxidase autoantibodies (TPOA IgG) using a commercial RIA kit (RSR 
Ltd, Cardiff, UK) following minor modification of the protocol.  
Positivity thresholds for RIAs 
The TGA assay positivity threshold (1.31 units) was set at the 97.5th 
percentile of 5470 children (median age 7.5 years, range 6.9 to 9.5 years) 
from the Avon Longitudinal Study of Parents and Children (ALSPAC), a 
population-based birth cohort study 29. Sera collected from healthy children 
attending schools in the Oxford and Windsor regions during 1989-1990 were 
tested to establish in-house positivity thresholds for TPOA and ATPA. The 
threshold for the ATPA assay was 21.6 units/ml, set at the 97.5th percentile 
of 318 schoolchildren tested (median age 11 years, range 9 -14 years). The 
threshold for the TPOA assay using the calibrators provided was 8.8 units/ml 
(kit threshold, 0.3 units/ml), set at the 97.5th percentile of 205 schoolchildren 
tested (median age 10 years, range 9-13 years).  
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HLA genotyping 
All DNA samples extracted from whole blood or mouth swab samples were 
whole genome amplified utilizing a PCR-based whole genome amplification 
protocol (Illustra GenomiPhi V2 DNA Amplification Kits). HLA class II 
genotype for high risk DR3-DQ2 (DRB1*03-DQA1*0501-DQB1*0201) and 
DR4-DQ8 (DRB1*04-DQA1*0301-DQB1*0302) and low risk DRX 
(representing all other HLA DRB1 variants) alleles was analyzed using PCR 
with sequence-specific primers as previously described 32. Genotypes were 
coded as either DR3-DQ2/DR3-DQ2, DR3-DQ2/DR4-DQ8, DR4-
DQ8/DR4-DQ8, DR3-DQ2/DRX, DR4-DQ8/DRX or DRX/DRX. The 
DRB1*0404 gene, recently reported to increase the risk of MA 33, was also 
analysed. 
Statistical analysis 
Data analysis was performed using IBM SPSS Statistics 23 software. 
Differences in categorical data were investigated by Chi-squared or Fisher’s 
Exact test. Non-parametric data analysis included Pearson correlation. 
Models adjusted for independent factors and covariates (age, gender, HLA 
DR-DQ) were analyzed by logistic regression; a two-tailed p value ˂0.05 
was considered statistically significant. The reference genotype for genetic 
analysis was DRX/DRX. 
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Results 
Prevalence of multiple autoimmunity in patients with T1D and non-genetic 
risk factors 
The distribution of non-islet autoantibodies in patients and schoolchildren is 
shown in ESM Figure 1. Overall, coeliac autoimmunity (TGA and/or CD) 
was detected in 9% (n=97, median age 9.7 years, median age at T1D onset 
8.7 years) of cases tested and was associated with younger age (OR 0.9, 
95%CI 0.8-0.9, p<0.0001). When those with a medical history of CD alone 
were not considered, TGA positivity was present in 7.3% (n=78) of patients.  
Gastric autoantibodies were detected in 8.2% of patients (n=87, median age 
12.8 years, median age at T1D onset 11 years), and were less common in 
children under 5 years of age (p<0.05). Thyroid autoantibodies were detected 
in 9.6% of patients (n=102, median age 13 years, median age at T1D onset 
11.7 years), and were associated with older age (OR 1.1, 95%CI 1.04-1.1, 
p=0.0001) (Figure 1). Thirty-three T1D patients (3.2%) had more than one 
type of non-islet autoantibody, and autoimmunity to TPO and H+/K+-
ATPase was the most common (n=23) combination of MA in individuals 
with T1D.  
Non-islet autoantibodies were not associated with T1D duration. All non-
islet autoantibodies were associated with female gender (OR 1.9, 95%CI 1.2-
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2.9, p=0.006; OR 2.1, 95%CI 1.3-3.3, p=0.002, OR 2.7, 95%CI 1.7-4.2, 
p<0.0001 and OR 3.4, 95%CI 1.6-7.2, p=0.002 for TGA/CD, ATPA, TPOA 
and multiple non-islet autoantibodies, respectively).  
Genetic risk factors for multiple autoimmunity in patients with T1D 
Haplotype analysis found significant associations of TGA/CD (OR 2.4, 
95%CI 1.4-3.9, p=0.001) and ATPA (OR 2.7, 95%CI 1.6-4.7, p=0.0003) 
with HLA DR3-DQ2. Gender analysis of HLA effects also identified an 
increased risk of ATPA in males carrying the DRB1*0404 allele (OR 2.9, 
95%CI 1.1-7.2, p=0.025) (Table 1).   
Genotype analysis showed that increased risk for TGA/CD was associated 
with DR3-DQ2/DR3-DQ2, DR4-DQ8/DR4-DQ8, DR3-DQ2/DRX and 
DR3-DQ2/DR4-DQ8 genotypes compared with the reference genotype 
DRX/DRX; OR 6.4 (95%CI 1.7-24.2, p=0.006), OR 6.0 (95%CI 1.5-22.9, 
p=0.009), OR 4.7 (95%CI 1.3-16.5, p=0.016), and OR 4.2 (95%CI 1.3-14.1, 
p=0.019), respectively. Risk for TPOA was associated with DR3-DQ2/DR3-
DQ2 (OR 2.7, 95%CI 1.1.-7.1, p=0.036), and risk for ATPA with DR3-
DQ2/DR4-DQ8 (OR 3.6, 95%CI 1.2-10.3, p=0.019). 
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Individuals with T1D who were seropositive for more than one non-islet 
autoantibody  
Of 1052 individuals tested for all 3 non-islet autoantibodies, 33 (3.1%) had 
antibodies of more than 1 specificity (ESM Table 1). No significant 
associations between HLA DR risk haplotypes and MA characterised by 
more than one non-islet autoantibody were observed.  In individuals with 
thyrogastric autoimmunity, the frequency of the HLA DR3-DQ2 (n=17; 
73.9%) and the HLA DR4-DQ8 (n=15; 65.2%) haplotypes was not different 
from the rest of the cohort (n=546; 57.3%, p=0.061, and n=702; 73.7%, 
p=0.565, respectively for DR3-DQ2 and DR4-DQ8). 
Islet-autoantibodies in patients with multiple autoimmunity 
Weak correlations of ATPA (r=0.184, p<0.0001) and TPOA (r=0.176, 
p<0.0001) with GADA positivity were observed, but no associations of non-
islet antibodies with IAA, IA-2A or ZnT8A were found.  
 
Discussion 
Although the association between T1D and other autoimmune disorders is 
well-known, and risk factors for each autoimmune disease have been 
investigated extensively, studies of MA, or autoimmune polyglandular 
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syndromes, are very limited, especially including genetic analysis 19, 30, 33. 
This study is the first population-based study in the UK to investigate the 
prevalence of MA in children and young adults with T1D, as well as genetic 
and non-genetic risk factors.  
Prevalence of multiple autoimmunity in T1D and non-genetic risk factors 
Multiple autoimmunity was common in patients with T1D diagnosed during 
childhood and adolescence. The prevalence of MA was higher in females 
and was strongly influenced by age. It was also strongly associated with 
HLA genotypes, particularly those including DR3-DQ2 haplotypes. 
Furthermore, risk of ATPA increased with DRB1*0404 in males. 
The high frequency of TGA in individuals with T1D established in this study 
is in line with previous reports 20, 23, 34-41. The prevalence of ATPA and TPOA 
was lower than previously reported (18-25%) 19, 30, 33, 41, 42, although 
exceeding that in the general population by up to 3 times. Discrepancies 
could be caused by differences in study design (population-based vs hospital-
based), use of different testing techniques, assay thresholds or variations in 
the age of the cohorts tested. For example, our patient cohort comprises 
children and young adults and we therefore based our threshold on a 
schoolchild cohort. Using the commercial kit threshold, which is based on 
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healthy adult blood donors, would increase the prevalence of TPOA in our 
patients to 17.2%. 
The detection of non-islet autoimmunity does not necessarily presage the 
onset of clinical disease, especially in those with levels close to the threshold. 
Complete clinical data were not available for the patients in this study and 
therefore we were unable to estimate the prevalence of latent disease or 
calculate predictive values for the different antibodies. However, it is likely 
that the majority of antibody positive patients will develop subclinical 
disease. While pernicious anaemia was found in only a minority of ATPA 
positive Belgian T1D patients, more than half of adult patients with parietal 
cell antibodies had autoimmune gastritis 43. Thyroid dysfunction was also 
common in those with TPOA 19. A Romanian study, found 87% of TPOA 
positive, but initially euthyroid patients with T1D progressed to subclinical 
hypothyroidism within 5±3.3 years44. The high prevalence of multiple 
autoimmunity we observed therefore, even from a relatively young age, 
supports the case for targeted screening of T1D patients. However, the 
optimal timing and frequency of autoantibody testing as an aid to cost-
effective diagnosis still needs to be determined. Prospective clinical studies 
of non islet autoimmunity in T1D patients are needed.   
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The increased risk for females developing most autoimmune diseases is well-
known 30, 33, 43, 45-48, with sex hormones speculated to be involved 43, 49. 
Coeliac-specific autoantibodies were more common in younger children 33, 
50-52, in contrast to ATPA and TPOA 19, 20, 33, 43, 53-55. However, as the majority 
of individuals in this cohort were tested close to T1D diagnosis, it was 
difficult to discriminate between the effects of age and age at T1D onset on 
non-islet autoantibody prevalence. 
The cross-sectional design of this study could not inform us as to the timing 
of seroconversion and we cannot identify which component of MA could 
trigger or predict another. However, the highest frequency of coeliac 
autoimmunity was in children with T1D diagnosed under 5 years, which may 
suggest the presence of shared causative factors predisposing to early 
development of these diseases. Later onset of gastric autoimmunity may 
suggest that infectious agents such as H.pylori or local gastric inflammation, 
which are more common in older age, could contribute to the loss of 
tolerance to ATPase 56, 57. The importance of H.pylori however, remains 
doubtful as these bacteria are detected in only 16% of autoimmune gastritis 
cases 58. An age-dependent increase in TPOA demonstrates the overall 
tendency of autoimmunity, especially thyroiditis, to develop more often in 
puberty and beyond 19, 43, 54, 55. Furthermore, while we have attempted to 
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match the median age of the schoolchild controls to those of the patients, the 
distribution of ages within the cohorts was different and this should be 
considered when interpreting these results. 
Our genetic findings provide additional evidence of the contribution of the 
HLA DR3-DQ2 haplotype to the risk of clustering of T1D, coeliac and 
thyroid autoimmunity 19, 33, 59-62, as well as novel information concerning its 
contribution to the clustering of T1D and gastric autoimmunity. The HLA 
DR4-DQ8/DR4-DQ8 genotype demonstrated an unexpectedly strong effect 
on risk (second after DR3-DQ2/DR3-DQ2) for developing coeliac 
autoimmunity in T1D patients, given the fact that the DR4-DQ8 haplotype 
shows a much weaker association with CD than DR3-DQ2 61. The observed 
risk effect of DRB1*0404 on the development of ATPA, replicates findings 
of a recent large study 30. No significant associations between genes and the 
presence of more than one non-islet autoantibody was observed, probably 
because of the small number of affected individuals, although an effect of 
the HLA DR3-DQ2 haplotype on the development of thyrogastric 
autoimmunity came close to significance. Further work is needed to reveal 
the precise contribution of HLA and non-HLA genes to the risk of MA. 
Overlap with islet autoantibodies 
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Our results confirm the overlap between ATPA/TPOA and GADA 15, 19, 20, 30, 
34, 35, 45 in spite of correction for HLA DR3-DQ2 and DR4-DQ8, genes which 
are known to predispose to GADA. This may suggest common disease 
pathways, given that the GAD65 enzyme is ubiquitously expressed in the 
pancreas, thyroid gland and stomach 63. Chance coincidence should also be 
considered however, as GADA and ATPA/TPOA tend to be more common 
in older age and in patients with a longer duration of T1D 19.  
 
Conclusion 
In summary, T1D is frequently associated with additional autoimmune 
conditions such as coeliac, gastric and thyroid disease, which are also 
characterized by production of organ-specific autoantibodies. Measurement 
of non-islet autoantibodies in young individuals with T1D is important for 
early detection of multiple autoimmunity as this can improve the in-time 
diagnosis and prognosis. Knowledge of the genetic and non-genetic risk 
factors predisposing to clustering of autoimmune diseases may allow a 
deeper understanding of shared pathogenetic mechanisms and inform 
targeted screening strategies. 
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Tables and figures 
Table 1. Summary of HLA DR-DQ effects on the development of 
multiple autoimmunity in individuals with T1D 
HLA DR-DQ TGA/CD (n=91) ATPA(n=79) TPOA (n=96) 
 
Haplotype Analysis 
DR3-DQ2 2.4, p=0.001  2.7, p=0.0003  1.3, p=0.251  
DR4-DQ8  0.9, p=0.556  
 
1.1, p=0.588 
 
0.8, p=0.432 
DRB1*0404 
 
1.3, p=0.457 1.6, p=0.106 1.6, p=0.127 
 
Genotype Analysis 
 
DR3-DQ2/DR3-DQ2 6.4, p=0.006  2.5, p=0.153  2.7, p=0.036 
DR3-DQ2/DR4-DQ8 4.2, p=0.019  3.6, p=0.019  1.3, p=0.498 
DR3-DQ2/DRX 4.7, p=0.016  2.6, p=0.104  1.4, p=0.506  
DR4-DQ8/DR4-DQ8 6.0, p=0.009  1.2, p=0.797  1.8, p=0.280  
DR4-DQ8/DRX 1.4, p=0.621  1.2, p=0.769  1.1, p=0.832  
 
Gender Analysis 
 
DR3-DQ2                    M 
F 
NS 
NS 
NS 
NS 
NS 
NS 
DR4-DQ8                    M                   
F  
NS 
NS 
NS 
NS 
NS 
NS 
DRB1*0404   M  
F 
NS 
NS 
2.9, p=0.025 
NS 
NS 
NS 
DR3-DQ2/DR3-DQ2  M                   
                                      F 
NS 
8.0, p=0.017 
NS 
NS 
NS 
7.3, p=0.007  
DR3-DQ2/DR4-DQ8  M   
                                      F  
NS 
NS 
NS 
5.0, p=0.033 
NS 
NS 
DR3-DQ2/DRX           M 
F 
NS 
NS 
NS 
NS 
NS 
NS 
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DR4-DQ8/DR4-DQ8  M       
                                      F 
NS 
7.9, p=0.013 
NS 
NS 
NS 
NS 
DR4-DQ8/DRX          M 
                                     F  
NS 
NS 
NS 
NS 
NS 
NS 
TGA/CD, ATPA and TPOA – antibodies to transglutaminase and/coeliac disease, 
antibodies to ATPase and antibodies to thyroid peroxidase, respectively. Odds ratios and 
p-values are represented. NS – not significant result (p>0.05). Increased risk of TGA/CD 
was linked to the DR3-DQ2 haplotype, with the highest risk in DR3-DQ2/DR3-DQ2 
individuals; Increased risk of ATPA was linked to DR3-DQ2, DRB1*0404 (in males) and 
DR3-DQ2/DR4-DQ8; Increased risk of TPOA was linked to DR3-DQ2/DR3-DQ2. 
Reference genotype – DRX/DRX. 
 
  
 25 
 
 
Figure 1. The prevalence of non-islet autoantibodies in children and 
young adults with T1D stratified by age group. The prevalence of TGA/CD 
reduced with age (p<0.0001), while ATPA were uncommon in children under 5 (p<0.05), 
and the prevalence of TPOA increased with age (p<0.0001). 
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(c) 
 
 
ESM Figure 1. The distribution of non-islet autoantibodies in healthy 
children and young patients with T1D. Antibody levels are shown for (a) TGA, 
(b) TPOA and (c) ATPA. The thresholds indicated by the dotted lines were set at the 
97.5th percentile of the 5470 children of the ALSPAC cohort for TGA, 318 schoolchildren 
for ATPA and 205 schoolchildren for TPOA. Those samples with levels below 1 TGA 
unit, 5 ATPA units/ml and 2 TPOA units/ml are represented by the numbers in boxes. 
The distribution of ATPA and TPOA levels in patients appears distinct from those of 
controls, while that of TGA seems similar in the two cohorts. 
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